Tower Research Capital LLC TRC Has $99,000 Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Tower Research Capital LLC TRC increased its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 1,488.6% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,104 shares of the company’s stock after acquiring an additional 10,405 shares during the period. Tower Research Capital LLC TRC’s holdings in Nurix Therapeutics were worth $99,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. BlackRock Inc. grew its holdings in shares of Nurix Therapeutics by 11.0% during the third quarter. BlackRock Inc. now owns 3,723,090 shares of the company’s stock worth $48,512,000 after purchasing an additional 367,743 shares during the last quarter. State Street Corp grew its stake in shares of Nurix Therapeutics by 9.2% during the third quarter. State Street Corp now owns 2,312,224 shares of the company’s stock valued at $30,128,000 after purchasing an additional 195,453 shares during the last quarter. ARK Investment Management LLC increased its holdings in shares of Nurix Therapeutics by 12.7% in the first quarter. ARK Investment Management LLC now owns 2,239,859 shares of the company’s stock valued at $19,890,000 after purchasing an additional 251,605 shares in the last quarter. Vanguard Group Inc. raised its position in Nurix Therapeutics by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,160,866 shares of the company’s stock worth $28,156,000 after purchasing an additional 49,370 shares during the last quarter. Finally, FMR LLC lifted its holdings in Nurix Therapeutics by 59.6% during the 2nd quarter. FMR LLC now owns 1,790,655 shares of the company’s stock worth $22,688,000 after buying an additional 668,632 shares in the last quarter. 90.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright dropped their target price on Nurix Therapeutics from $53.00 to $33.00 and set a “buy” rating for the company in a research report on Monday, July 24th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $27.22.

Nurix Therapeutics Trading Up 1.8 %

Shares of NASDAQ NRIX opened at $8.65 on Monday. The company has a fifty day moving average price of $9.36 and a 200 day moving average price of $9.67. The firm has a market cap of $416.93 million, a PE ratio of -2.91 and a beta of 1.63. Nurix Therapeutics, Inc. has a 1-year low of $8.22 and a 1-year high of $16.81.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Thursday, July 13th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.12. Nurix Therapeutics had a negative return on equity of 53.36% and a negative net margin of 258.37%. The business had revenue of $30.68 million for the quarter, compared to analyst estimates of $21.96 million. Equities research analysts forecast that Nurix Therapeutics, Inc. will post -2.88 EPS for the current year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.